MALVERN, Pa., Dec. 10, 2013 /PRNewswire/ — Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013. Recognized for his strategic capabilities, Mr. Higgins has over 30 […]
Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo’s approach, using its proprietary and highly specific […]
– Interim Analyses from Phase 3 Pediatric Studies Suggest Prolonged Half-Life of Investigational Long-Lasting Therapies in Children Under Age 12 – CAMBRIDGE, Mass. & STOCKHOLM–(December 9, 2013)–Today Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) announced new results from Phase 3 studies of their investigational long-lasting recombinant factor IX and VIII Fc fusion protein candidates for […]
RetroArc Extends the AMS™ Continence Sling Portfolio to Provide More Options for Women With SUI MINNEAPOLIS, Dec. 9, 2013 /PRNewswire/ — American Medical Systems® Inc. (AMS), an Endo Health Solutions Inc. (Nasdaq: ENDP) subsidiary and leading provider of devices and therapies for male and female pelvic health, today announced FDA 510(k) Clearance of its RetroArc™ Retropubic Sling System for treatment of female stress […]
NEW YORK– December 9, 2013 — (BUSINESS WIRE) –Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden the organization as part of Project Rejuvenate. “Today we are announcing an important step to rejuvenate our company by creating the first Forest Executive Team […]
57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]
Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]
Undetectable Viral Load Sustained Over 20 Weeks in SB-728-902 Study; Data Demonstrate Dose Response in SB-728-1101 Cytoxan Study; Reduction of Viral Reservoir Observed in All Immune Non-Responders Over Three Years RICHMOND, Calif., Dec. 6, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from all dose cohorts in the Company’s ongoing clinical trials (SB-728-1101 […]
– Sovaldi Approved for Use in Genotypes 1, 2, 3 or 4 – – High Cure Rates (SVR12) and Shortened, 12-Week Course of Therapy for Many Patients – – First Ever Oral Treatment Regimen for Genotypes 2 or 3 – – First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence – FOSTER CITY, […]
– Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal – PARIS, Dec. 5, 2013 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia® (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast […]